Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis

NCT06453317 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

172

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis
Inflammatory Bowel Diseases

Interventions

BIOLOGICAL: Infliximab
BIOLOGICAL: Ustekinumab

Sponsor

Medical University of Lodz

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]